ADPT

Adaptive Biotechnologies Corporation (ADPT) Economic Moat Analysis (2026)

Invetso Score: 3.4/10 — Weak · Last Updated: 2026-08-01

Overall Score

Scale Pricing Power

Gross margin remains strong at 75.4%, indicating some pricing power in the core business.

Revenue per share is $1.95, but the company still trades at a high EV/Sales multiple of 13.7x.

Profitability Efficiency

Operating margins remain negative, with EBIT margin at -10.4% and operating profit margin at -12.2%.

Return on invested capital is still negative at -6.7%, showing the business is not yet generating economic profits.

Cash conversion remains weak, with operating cash flow margin at -6.8% and free cash flow yield at -0.6%.

Balance Sheet Resilience

Liquidity is solid, with a current ratio of 4.8x and quick ratio of 4.7x.

Debt leverage remains manageable relative to market value, with debt-to-market-cap at 8.6%, though debt-to-equity is elevated at 2.9x.

Cash per share of $2.18 provides a cushion despite ongoing losses.

Moat Durability Intangibles

High R&D intensity at 28.6% of revenue suggests continued investment in product development, but it has not yet translated into durable profitability.

Stock-based compensation remains meaningful at 11.6% of revenue, which can dilute moat economics.

The company’s intangible asset base is moderate, with intangibles at 18.7% of total assets.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Adaptive Biotechnologies Corporation. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →